Escin‐sorafenib synergy up‐regulates LC3‐II and p62 to induce apoptosis in hepatocellular carcinoma cells

Author:

Hussain Yusuf12,Singh Jyoti13,Meena Abha12ORCID,Sinha Rohit Anthony4,Luqman Suaib12

Affiliation:

1. Bioprospection and Product Development Division CSIR‐Central Institute of Medicinal and Aromatic Plants Lucknow India

2. Academy of Scientific and Innovative Research (AcSIR) Ghaziabad India

3. Jawaharlal Nehru University New Delhi India

4. Department of Endocrinology Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India

Abstract

AbstractIntroductionHepatocellular carcinoma (HCC) is a common solid cancer and the leading cause of cancer deaths worldwide. Sorafenib is the first drug used to treat HCC but its effectiveness needs to be improved, and it is important to find ways to treat cancer that combine sorafenib with other drugs. Synergistic therapies lower effective drug doses and side effects while enhancing the anticancer effect.PurposeIn the present study, the therapeutic potential of sorafenib in combination with escin and its underlying mechanism in targeting liver cancer has been established.Study Design/MethodsThe IC50 of sorafenib and escin against HepG2, PLC/PRF5 and Huh7 cell lines were determined using MTT assay. The combination index, dose reduction index, isobologram and concentrations producing synergy were evaluated using the Chou‐Talaly algorithm. The sub‐effective concentration of sorafenib and escin was selected to analyze cytotoxic synergistic potential. Cellular ROS, mitochondrial membrane potential, annexin V and cell cycle were evaluated using a flow‐cytometer, and autophagy biomarkers were determined using western blotting. Moreover, autophagy was knocked down using ATG5 siRNA to confirm its role. A DEN‐induced liver cancer rat model was developed to check the synergy of sorafenib and escin.ResultsDifferent concentrations of escin reduced the IC50 of sorafenib in HepG2, PLC/PRF5 and Huh7 cell lines. Chou‐Talaly algorithm determined cytotoxic synergistic concentrations of sorafenib and escin in these cell lines. Mechanistically, this combination over‐expressed p62 and LC‐II, reflecting autophagy block and induced late apoptosis, further reconfirmed by ATG5 knockdown. Sorafenib and escin combination  reduced HCC serum biomarker α‐feto protein (α‐FP) by 1.5 folds. This combination restricted liver weight, tumor number and size, also, conserved morphological features of liver cells. The combination selectively targeted the G0/G1 phase of cancer cells.ConclusionEscin and sorafenib combination potentially up‐regulates p62 to block autophagy to induce late apoptosis in liver cancer cells.

Funder

Council of Scientific and Industrial Research, India

Department of Science and Technology, Ministry of Science and Technology, India

Publisher

Wiley

Subject

Health, Toxicology and Mutagenesis,Management, Monitoring, Policy and Law,Toxicology,General Medicine

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3